Wuzhi Capsule Dosage Affects Tacrolimus Elimination in Adult Kidney Transplant Recipients, as Determined by a Population Pharmacokinetics Analysis
Lizhi Chen,Yunyun Yang,Xuebin Wang,Chenyu Wang,Weiwei Lin,Zheng Jiao,Zhuo Wang
DOI: https://doi.org/10.2147/PGPM.S321997
2021-09-03
Pharmacogenomics and Personalized Medicine
Abstract:Lizhi Chen, 1, &ast Yunyun Yang, 1, 2, &ast Xuebin Wang, 1, &ast Chenyu Wang, 2 Weiwei Lin, 3 Zheng Jiao, 2, 4 Zhuo Wang 1 1 Department of Pharmacy, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, People's Republic of China; 2 Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, People's Republic of China; 3 Department of Pharmacology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, People's Republic of China; 4 Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zheng Jiao Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 Huaihai West Road, Shanghai, 200030, People's Republic of China Tel +86 21 2220 0000 ext 3021 Email Zhuo Wang Department of Pharmacy, Shanghai Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai, 200433, People's Republic of China Tel/Fax +86-21-31162299 Email Purpose: In this study, we aimed to establish a tacrolimus population pharmacokinetic model and better understand the drug-drug interaction between Wuzhi capsule and tacrolimus in Chinese renal transplant recipients. Patients and Methods: We performed a population pharmacokinetic analysis using a non-linear mixed-effects model to determine the suitable Wuzhi capsule dose in combination with tacrolimus. Data on 1378 tacrolimus steady-state concentrations were obtained from 142 patients who received kidney transplant in Changhai Hospital and Huashan Hospital. Demographic characteristics, laboratory tests, genetic polymorphisms, and co-medications were evaluated. Results: The one-compartment model best described data. Our final model identified creatinine clearance rate, hematocrit, Wuzhi capsule dose, CYP3A5&ast3 genetic polymorphisms, and tacrolimus daily dose as significant covariates for tacrolimus clearance, with the value of 14.4 L h − 1 , and the between-subject variability (BSV) was 25.4%. The Wuzhi capsule showed a dose-dependent effect on tacrolimus pharmacokinetics, demonstrating a stronger inhibitory effect than inductive effect. Conclusion: Our model can accurately describe population pharmacokinetics of tacrolimus when combined with different doses of Wuzhi capsule. Additionally, this model can be used for individualizing tacrolimus dose following kidney transplantation. Keywords: renal transplantation, inhibitory effect, one-compartment model, CYP3A5 Tacrolimus (FK506) is an efficacious immunosuppressive drug used following solid organ transplant; 1 however, it has a narrow therapeutic range and large between-patient variability. The bioavailability of tacrolimus is low and highly variable (range 4–89%) owing to its poor solubility and extensive first-pass effect. 2 Therapeutic drug monitoring (TDM) is implemented to individualize the dosage of tacrolimus based on the trough concentration (C 0 ) and to reduce the risks of toxicity and rejection risk. 3 In general, pharmacokinetic parameters reach a steady state approximately 3 d following therapy initiation. Therefore, early identification of factors that can affect pharmacokinetic biomarkers can facilitate the adjustment of tacrolimus dosage. A population pharmacokinetic (popPK) modeling using the Bayesian estimation is commonly used to quantitatively assess the dependency between a covariate and a pharmacokinetic parameter for identifying inter- and intra-individual variabilities in the estimated pharmacokinetic parameter and the relevant covariate. 4 Currently, there are numerous popPK models, 5–9 which have been developed to characterize the pharmacokinetics of tacrolimus in adults after kidney transplant. Several factors have been identified to affect tacrolimus pharmacokinetics, including demographic characteristics; CYP3A5, CYP3A4 , and ABCB1 genotypes; hematocrit; post-operative days; tacrolimus daily dose; and drug–drug interactions. The tacrolimus doses recommended by the Food and Drug Administration (FDA) are according to patient age, type of transplanted organ, post-transplant day, and immunosuppressive therapy regimens. 10 Tacrolimus is metabolized in the liver by cytochrome CYP3A isoenzymes and excreted primarily through faces (approximately 93%). The CYP3A5*3 allele affects tacrolimus pharmacokinetics in organ transplant recipients, and thus dose adjustment based on the CYP3A -Abstract Truncated-
pharmacology & pharmacy